JP7558167B2 - オリゴベンズアミド類似体およびがん処置におけるそれらの使用 - Google Patents

オリゴベンズアミド類似体およびがん処置におけるそれらの使用 Download PDF

Info

Publication number
JP7558167B2
JP7558167B2 JP2021531522A JP2021531522A JP7558167B2 JP 7558167 B2 JP7558167 B2 JP 7558167B2 JP 2021531522 A JP2021531522 A JP 2021531522A JP 2021531522 A JP2021531522 A JP 2021531522A JP 7558167 B2 JP7558167 B2 JP 7558167B2
Authority
JP
Japan
Prior art keywords
compound
substituted
alkyl
aralkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510374A5 (https=
JP2022510374A (ja
Inventor
ガネシュ ラジ
ジュン－モ アーン
ラトナ ケイ． バドラムディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2022510374A publication Critical patent/JP2022510374A/ja
Publication of JP2022510374A5 publication Critical patent/JP2022510374A5/ja
Priority to JP2024159696A priority Critical patent/JP7770716B2/ja
Application granted granted Critical
Publication of JP7558167B2 publication Critical patent/JP7558167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
JP2021531522A 2018-12-03 2019-12-02 オリゴベンズアミド類似体およびがん処置におけるそれらの使用 Active JP7558167B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024159696A JP7770716B2 (ja) 2018-12-03 2024-09-17 オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774671P 2018-12-03 2018-12-03
US62/774,671 2018-12-03
PCT/US2019/064073 WO2020117715A1 (en) 2018-12-03 2019-12-02 Oligo-benzamide analogs and their use in cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024159696A Division JP7770716B2 (ja) 2018-12-03 2024-09-17 オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Publications (3)

Publication Number Publication Date
JP2022510374A JP2022510374A (ja) 2022-01-26
JP2022510374A5 JP2022510374A5 (https=) 2022-12-08
JP7558167B2 true JP7558167B2 (ja) 2024-09-30

Family

ID=70973687

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531522A Active JP7558167B2 (ja) 2018-12-03 2019-12-02 オリゴベンズアミド類似体およびがん処置におけるそれらの使用
JP2024159696A Active JP7770716B2 (ja) 2018-12-03 2024-09-17 オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024159696A Active JP7770716B2 (ja) 2018-12-03 2024-09-17 オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Country Status (8)

Country Link
US (2) US12275685B2 (https=)
EP (1) EP3891123A4 (https=)
JP (2) JP7558167B2 (https=)
KR (1) KR20210100115A (https=)
AU (1) AU2019393770B2 (https=)
CA (1) CA3121247A1 (https=)
SG (1) SG11202105276TA (https=)
WO (1) WO2020117715A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024178254A (ja) * 2018-12-03 2024-12-24 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023154856A1 (en) * 2022-02-11 2023-08-17 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078288A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds for use in treating cancers

Family Cites Families (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
AU2004231248B2 (en) 1996-10-31 2008-05-15 Human Genome Sciences, Inc. Streptococcus pneumoniae Polynucleotides and Sequences
US6027892A (en) 1996-12-30 2000-02-22 Chang Esther H Compositions and methods for reducing radiation and drug resistance in cells
AU9209898A (en) 1997-09-02 1999-03-22 Ricex Company, Inc., The A method for treating hypercholesterolemia, hyperlipidemia, and atherosclerosis
EP1105474A2 (en) 1998-05-14 2001-06-13 Chiron Corporation Human genes and gene expression products v
WO1999064626A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
AU2342900A (en) 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
US6166177A (en) 1998-12-08 2000-12-26 Corixa Corporation Compounds and methods for the treatment and diagnosis of chlamydial infection
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
JP4799736B2 (ja) 1999-02-22 2011-10-26 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体フラグメント標的化イムノリポソーム
US6401043B1 (en) 1999-04-26 2002-06-04 Variagenics, Inc. Variance scanning method for identifying gene sequence variances
AU2005200246A1 (en) 1999-04-30 2005-02-17 Novartis Vaccines And Diagnostics, Inc. Neisseria genomic sequences and methods of their use
US6962989B1 (en) 1999-07-08 2005-11-08 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding novel proteins
US6727063B1 (en) 1999-09-10 2004-04-27 Millennium Pharmaceuticals, Inc. Single nucleotide polymorphisms in genes
US7323496B2 (en) 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
EP1234174A1 (en) 1999-12-02 2002-08-28 Myriad Genetics, Inc. Protein-protein interactions
GB2361238B (en) 2000-02-04 2002-03-06 Aeomica Inc Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human heart
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
GB2360284B (en) 2000-02-04 2002-02-27 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human heart
AU2001245489A1 (en) 2000-03-07 2001-09-17 Whitehead Institute For Biomedical Research Human single nucleotide polymorphisms
DE10019058A1 (de) 2000-04-06 2001-12-20 Epigenomics Ag Detektion von Variationen des DNA-Methylierungsprofils
IL151872A0 (en) 2000-03-24 2003-04-10 Micromet Ag mRNA AMPLIFICATION
US20040048816A1 (en) 2000-03-24 2004-03-11 Zohlnhoefer Dietlind Restenosis treatment
AU2007203337B2 (en) 2000-04-18 2009-12-17 Virco Bvba Methods for measuring drug resistance
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
US20040005559A1 (en) 2000-07-24 2004-01-08 Loring Jeanne F. Markers of neuronal differentiation and morphogenesis
CA2414421A1 (en) 2000-07-31 2002-02-07 Gene Logic, Inc. Molecular toxicology modeling
EP1334113A4 (en) 2000-10-20 2007-08-08 Expression Diagnostics Inc EVALUATION OF LEUCOCYTAIRE EXPRESSION LEVEL
US20030228618A1 (en) 2000-11-24 2003-12-11 Erez Levanon Methods and systems for identifying naturally occurring antisense transcripts and methods, kits and arrays utilizing same
US20030154032A1 (en) 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
US20040005557A1 (en) 2001-01-16 2004-01-08 Muralidhara Padigaru Proteins, polynucleotides encoding them and methods of using the same
WO2002068647A2 (en) 2001-01-16 2002-09-06 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
US20040005558A1 (en) 2001-01-18 2004-01-08 Anderson David W. Proteins, polynucleotides ecoding them and methods of using the same
EP1368468A4 (en) 2001-02-23 2005-02-16 Human Genome Sciences Inc HUMAN SEMINAR PROTEINS
JP2004536575A (ja) 2001-02-28 2004-12-09 コンドロジーン・インコーポレイテッド 変形性関節症に関連する組成物および方法
US20030119010A1 (en) 2001-03-01 2003-06-26 University Of Queensland Polynucleotides and polypeptides linked to a disease or condition
CA2419492C (en) 2001-03-22 2005-07-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methods and apparatus for gel-free qualitative and quantitative proteome analysis, and uses therefore
AUPR416301A0 (en) 2001-04-02 2001-05-03 State Of Queensland Through Princess Alexandra Hospital And District Health Services, The Polynucleotides and polypeptides linked to neuropsychiatric di sorders
EP1402341A4 (en) 2001-06-15 2004-09-15 Chiron Corp ESSENTIAL AND IMPORTANT GENES OF PSEUDOMONAS AERUGINOSA AND THEIR USE FOR THE DESIGNATION OR IDENTIFICATION OF ANTIBACTERIAL AGENTS
AU2002365904A1 (en) 2001-07-10 2003-09-04 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
US20030170678A1 (en) 2001-10-25 2003-09-11 Neurogenetics, Inc. Genetic markers for Alzheimer's disease and methods using the same
MXPA04004378A (es) 2001-11-07 2004-09-10 Univ Arkansas Diagnostico, prognosis e identificacion de objetivos terapeuticos potenciales de mieloma multiple basado en el perfilado de expresion de genes.
US20040209253A1 (en) 2001-11-07 2004-10-21 Tam Joseph Wing On SNP-based HLA-DP, DR and DQ genotyping analysis by reversed dot blot flow through hybridization
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US7074559B2 (en) 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
AU2003222128A1 (en) 2002-03-29 2003-10-13 Genomatica, Inc. Human metabolic models and methods
WO2003106706A2 (en) 2002-06-14 2003-12-24 Millenium Biologix Ag Identification of tissue/cell specific marker genes and use thereof
AU2003247610A1 (en) 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
AU2003252136A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
US20050058689A1 (en) 2003-07-03 2005-03-17 Reactive Surfaces, Ltd. Antifungal paints and coatings
CA2500521A1 (en) 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
AU2003284239B2 (en) 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
AU2003295462A1 (en) 2002-11-13 2004-06-03 Incyte Corporation Lipid-associated proteins
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US20070077553A1 (en) 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
PT1572233E (pt) 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
JP2006517032A (ja) 2003-01-28 2006-07-13 ジョージタウン・ユニバーシティ ある種の癌治療の有効性を評価するための方法
US20070004621A1 (en) 2003-02-12 2007-01-04 Viji Shridhar Bex4 nucleic acids, polypeptides, and method of using
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1629119A2 (en) 2003-04-29 2006-03-01 Wyeth Methods for diagnosing aml and mds by differential gene expression
DK1633327T3 (da) 2003-06-04 2010-11-15 Univ Georgetown Fremgangsmåde til forbedring af stabilitet og opbevaringslevetid af liposomkomplekser
ATE420160T1 (de) 2003-06-18 2009-01-15 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
WO2005000882A2 (en) 2003-06-27 2005-01-06 University College Cork - National University Of Ireland, Cork Dna fragments and proteins encoded by said dna isolated from bifidobacteria
EP1641940A4 (en) 2003-07-01 2009-09-02 Mor Research Applic Ltd DETERMINING PROGNOSIS IN PATIENTS WITH EWING SARCOMA BY GENETIC PROFILES
US20060281091A1 (en) 2003-07-07 2006-12-14 Lavedan Christian N Genes regulated in ovarian cancer a s prognostic and therapeutic targets
US20050209181A1 (en) 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
AU2005206389A1 (en) 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
EP1713900A4 (en) 2004-01-27 2009-06-17 Compugen Ltd METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES
AU2005288710A1 (en) 2004-01-27 2006-04-06 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
CA2554782C (en) 2004-02-03 2013-08-13 Emory University Methods to manufacture 1,3-dioxolane nucleosides
CA2555989A1 (en) 2004-02-24 2005-09-01 Innogenetics N.V. Method for determining the risk of developing a neurological disease
US7183057B2 (en) 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
JP2007533005A (ja) 2004-04-07 2007-11-15 ジーン ロジック インコーポレイテッド 肝毒性分子モデル
WO2005123113A2 (en) 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
JP2006000015A (ja) 2004-06-15 2006-01-05 Kazuhito Rokutan ストレスの評価方法
US20060210967A1 (en) 2004-07-02 2006-09-21 Agan Brian K Re-sequencing pathogen microarray
JP2008506776A (ja) 2004-07-19 2008-03-06 メルク　エンド　カムパニー　インコーポレーテッド ヒストン脱アセチル化酵素阻害剤
EP2471536A1 (en) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroid analogs and characterization and treatment methods
US20070238100A1 (en) 2004-11-30 2007-10-11 Mcglennen Ronald C Integrated methodologies for the detection and genotyping of human papillomaviruses
EP1836221B1 (en) 2004-12-02 2011-08-03 Csir Gram positive bacterial cells comprising a disrupted flagellin gene, flagellin-based fusion proteins and use in removal of metal ions from a liquid
TW200633718A (en) 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
US7943306B2 (en) 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
WO2006077025A2 (en) 2005-01-18 2006-07-27 F. Hoffmann-La Roche Ag Morpholines as 5ht2c agonists
AU2006207453A1 (en) 2005-01-21 2006-07-27 Innogenetics N.V. Nucleic acid variants in the ficolin genes associated with altered innate immunity
GB0502042D0 (en) 2005-02-01 2005-03-09 Univ Glasgow Materials and methods for diagnosis and treatment of chronic fatigue syndrome
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
EP1696040A1 (en) 2005-02-28 2006-08-30 Eurofins Viralliance, Inc. Method of genotyping and phenotyping hepatitis B viruses resistant to antiviral molecules
US20060246484A1 (en) 2005-03-10 2006-11-02 Hare Joshua M Identification of gene expression by heart failure etiology
ES2494840T3 (es) 2005-03-15 2014-09-16 Fujirebio Europe N.V. Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas
EP1858915B1 (en) 2005-03-15 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Variants of hepatitis b virus resistant against some nucleoside analogues, but sensitive to others, and uses thereof
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2009501522A (ja) 2005-07-12 2009-01-22 コドン デバイシズ インコーポレイテッド 生体触媒工学のための組成物及び方法
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
JP2009507484A (ja) 2005-09-09 2009-02-26 クアーク・ファーマスーティカルス、インコーポレイテッド オリゴリボヌクレオチドおよび心臓血管疾患の治療のためのその使用法
CA2624086A1 (en) 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
DE102005048828B4 (de) 2005-10-12 2013-03-28 Evocatal Gmbh Fluoreszenzmarker und dessen Verwendung
TW200730825A (en) 2005-10-21 2007-08-16 Genenews Inc Method and apparatus for correlating levels of biomarker products with disease
EP1844164B1 (en) 2005-11-15 2010-07-14 Genoid KFT Method of detecting pathogens using molecular beacons
KR20080080525A (ko) 2005-12-08 2008-09-04 노파르티스 아게 유전자 전사에 대한 ｆｇｆｒ３의 억제제의 효과
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
GB0600927D0 (en) 2006-01-17 2006-02-22 Glaxosmithkline Biolog Sa Assay and materials therefor
MX2008011477A (es) 2006-03-07 2008-09-23 Cargill Inc Aldolasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas.
AU2007223086B2 (en) 2006-03-07 2013-09-26 Basf Enzymes Llc Aldolases, nucleic acids encoding them and methods for making and using them
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP2013230A2 (en) 2006-04-21 2009-01-14 Transgene S.A. Hpv-16-based papillomavirus vaccine
AU2007242061B2 (en) 2006-04-21 2012-11-29 Intervet International B.V. Pestivirus species
BRPI0710242A2 (pt) 2006-04-21 2011-08-09 Transgene Sa uso de uma composição
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
MXNL06000069A (es) 2006-09-15 2008-10-09 Inst Potosino De Investigacion Sistema para expresar y transportar proteinas recombinantes al periplasma de escherichia coli por vía de secreción tat.
WO2008082730A2 (en) 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
AU2007347152A1 (en) 2006-09-25 2008-08-21 Regents Of The University Of Colorado Compositions and methods for tissue-based protein truncation test for disease diagnosis
US7960110B2 (en) 2006-11-15 2011-06-14 The Regents Of The University Of California Detection of chromosomal region copy number changes to diagnose melanoma
EP2712930A3 (en) 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
US20100028334A1 (en) 2006-12-15 2010-02-04 Trustees Of Boston University Compositions and methods to potentiate colistin activity
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
WO2008109773A2 (en) 2007-03-06 2008-09-12 Cornell Research Foundation, Inc. Chronic obstructive pulmonary disease susceptibility and related compositions and methods
US7816324B2 (en) 2007-03-13 2010-10-19 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
US8236983B2 (en) 2008-03-13 2012-08-07 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by apoptosis
EP2559771A3 (en) 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
EP2171084B1 (en) 2007-06-01 2012-02-01 Agendia B.V. Prognostic gene expression signature for non small cell lung cancer patients
CA2692546C (en) 2007-07-09 2018-03-13 Esther H. Chang Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
WO2009022939A1 (en) 2007-08-09 2009-02-19 Uchrezhdenie Rossiiskoi Akademii Nauk Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Ran (Imb Ran) Method for identifying the genotype and subtype of hepatitis c virus on a biological microchip
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009047756A2 (en) 2007-10-11 2009-04-16 Bioview Ltd. Methods and kits for diagnosing lung cancer
US9435001B2 (en) 2007-11-01 2016-09-06 Self-Screen B.V. Detection method for cervical HPVS
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
CN101186636A (zh) 2007-12-06 2008-05-28 三峡大学 人乳头瘤病毒外壳蛋白l1短肽及其应用
WO2009101968A1 (ja) 2008-02-14 2009-08-20 Gene Techno Science Co., Ltd. 抗ａｄａｍ－１５抗体及びその利用
WO2009121031A1 (en) 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
JP2010088432A (ja) 2008-09-09 2010-04-22 Kansetsu Saisei Kenkyusho:Kk Ｔｎｆ阻害薬治療による有効性・副作用発現に関する多型、およびその利用
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2352369B1 (en) 2008-12-04 2017-04-26 Sangamo BioSciences, Inc. Genome editing in rats using zinc-finger nucleases
US9434771B2 (en) 2008-12-17 2016-09-06 The Johns Hopkins University Compositions and methods for diagnosing and treating inflammatory bowel disease and related disorders
BRPI0903187B1 (pt) 2009-09-09 2018-12-18 Fundação Oswaldo Cruz método de predição da resposta clínica do paciente infectado pe1o vírus da dengue durante os primeiros dias após o início dos sintomas, método de diagnóstico de infecção pelo vírus da dengue, e, kit para determinar o prognóstico da resposta clínica do paciente infectado por dengue
US20120178111A1 (en) 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
JP2013508096A (ja) 2009-10-23 2013-03-07 イバンティス インコーポレイテッド 眼内移植システムおよび眼内移植方法
EP2494073B1 (de) 2009-10-26 2017-11-29 AGCT GmbH Konjugate von nukleotiden und methoden zu deren anwendung
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
JP2011184308A (ja) 2010-03-04 2011-09-22 Shiseido Co Ltd 皮膚外用剤
DK2569446T3 (en) 2010-05-12 2018-10-29 Steven E Schutzer DIAGNOSTIC MARKERS FOR NEUROPsychiatric Disease
EA201291460A1 (ru) 2010-05-28 2013-11-29 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Олигобензамидные соединения и их применение
TW201217533A (en) 2010-08-04 2012-05-01 Bayer Pharma AG Genomics of actinoplanes utahensis
US20130216557A1 (en) 2010-08-14 2013-08-22 Biogen Idec Ma Inc. Ltbr blockade: methods for optimizing therapeutic responsiveness of patients
EP2606165B1 (en) 2010-08-16 2016-10-12 Sinai Health System Markers of the male urogenital tract
CA2817256A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
CZ303405B6 (cs) 2011-02-14 2012-08-29 Ústav informatiky AV CR, v. v. i. Zpusob identifikace osob se zvýšeným genetickým rizikem výskytu infarktu myokardu
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
BR112013027448A2 (pt) 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research terapia de combinação com hsp90
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP2758519B1 (en) 2011-09-21 2017-03-29 King Abdullah University Of Science And Technology Didemnin biosynthetic gene cluster in tistrella mobilis
WO2013063439A1 (en) 2011-10-27 2013-05-02 University Of Louisville Research Foundation, Inc. Characterizing melanoma
EP2773191A2 (en) 2011-10-31 2014-09-10 Merck Sharp & Dohme Corp. Alzheimer's disease signature markers and methods of use
WO2013078277A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
US20150152474A1 (en) 2012-03-09 2015-06-04 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
WO2013143700A2 (en) 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
MX362981B (es) 2012-03-27 2019-02-28 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
HK1208470A1 (en) 2012-03-29 2016-03-04 Biogen Ma Inc. Biomarkers for use in integrin therapy applications
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US20150133420A1 (en) 2012-05-04 2015-05-14 The Regents Of The University Of California Broad antiviral therapy with membrane modifying oxysterols
AU2013293270B2 (en) 2012-07-25 2018-08-16 Massachusetts Institute Of Technology Inducible DNA binding proteins and genome perturbation tools and applications thereof
EP2703496A1 (en) 2012-08-31 2014-03-05 Innogenetics N.V. Combination of PCR primers and a method for detection and identification of Human Papillomavirus (HPV)
EP3677310A1 (en) 2012-10-08 2020-07-08 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
WO2014089124A1 (en) 2012-12-03 2014-06-12 Cenexys, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
AU2013361323B2 (en) 2012-12-19 2018-09-06 Caris Science, Inc. Compositions and methods for aptamer screening
US20140243211A1 (en) 2013-02-28 2014-08-28 Indiana University Research & Technology Corporation Blood biomarkers for suicidality
US20140271644A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
US20150151004A1 (en) 2013-06-14 2015-06-04 The University Of Kansas Methods and compositions of modulating tumor initiating cells and the use thereof
WO2015035235A1 (en) 2013-09-06 2015-03-12 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Compositions and methods for increasing mesenchymal stromal cell migration to tumors
US10597696B2 (en) 2013-09-18 2020-03-24 University Of Notre Dame Du Lac Detection of Niemann-Pick disease comprising detection of lysozyme and cathepsins
CN106170302B (zh) 2014-04-04 2020-11-06 国立大学法人大阪大学 含有使溶血磷脂受体活化的物质的药剂递送促进剂
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
WO2016081941A1 (en) 2014-11-21 2016-05-26 Caris Science, Inc. Oligonucleotide probes and uses thereof
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
US20160339022A1 (en) 2015-04-17 2016-11-24 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibitors
KR102004930B1 (ko) 2015-06-29 2019-07-29 연세대학교 원주산학협력단 저대사 유도물질 t1am을 이용한 근위축 유도제 및 이의 근비대 치료 용도
AU2016327461A1 (en) 2015-09-25 2018-04-26 The University Of British Columbia Suppressors of premature termination codons as therapeutics and methods for their use
WO2017059147A1 (en) 2015-09-29 2017-04-06 Janssen Pharmaceuticals, Inc. Combination therapy regimen for treatment of hcv
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
KR102541256B1 (ko) 2015-11-30 2023-06-12 (주)아모레퍼시픽 Lipa 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법
EP3403099A4 (en) 2016-01-15 2019-09-04 The Wistar Institute Of Anatomy And Biology METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CA3011939A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
US20180059115A1 (en) 2016-08-05 2018-03-01 The Wistar Institute Of Anatomy And Biology Methods for monitoring polymorphonuclear myeloid derived suppressor cells, and compositions and methods of treatment of cancer
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US11535597B2 (en) 2017-01-18 2022-12-27 The Scripps Research Institute Photoreactive ligands and uses thereof
WO2018149359A1 (zh) 2017-02-17 2018-08-23 武汉朗来科技发展有限公司 三氮唑抗菌衍生物、其药物组合物和用途
AU2018235957B2 (en) 2017-03-16 2024-02-01 Seattle Children's Hospital (dba Seattle Children's Research Institute) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
CA3056911A1 (en) 2017-03-23 2018-09-27 Meharry Medical College Methods for diagnosing and treating inflammatory bowel disease
CA3057368A1 (en) 2017-03-27 2018-10-04 Caris Science, Inc. Oligonucleotide probes and uses thereof
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
CN120992952A (zh) 2017-06-20 2025-11-21 梅哈里医学院 靶向defa5抗体和用于诊断和治疗炎性肠病的测定方法
WO2019046815A1 (en) 2017-08-31 2019-03-07 Poseida Therapeutics, Inc. TRANSPOSON SYSTEM AND METHODS OF USE
AU2018329741B2 (en) 2017-09-08 2025-02-20 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
RU2770922C2 (ru) 2017-09-20 2022-04-25 4Д Молекьюлар Терапьютикс Инк. Капсиды вариантов аденоассоциированных вирусов и методы их применения
AU2018352221B2 (en) 2017-10-16 2024-04-18 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of mRNA
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
WO2019108951A1 (en) 2017-12-01 2019-06-06 Dana-Farber Cancer Institute, Inc. Compositions and methods for inhibiting dhhc-type palmitoyltransferases for cancer treatment
TWI908706B (zh) 2018-03-07 2025-12-21 美商波西達治療公司 ＣＡＲＴｙｒｉｎ組成物和使用方法
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
CA3103404A1 (en) 2018-06-11 2019-12-19 Indiana University Research And Technology Corporation Methods for assessment and early detection of stress, selecting and monitoring treatment, and new use for drugs
EP3830301B1 (en) 2018-08-01 2024-05-22 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
AU2019335014A1 (en) 2018-09-05 2021-03-25 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CA3119749A1 (en) 2018-11-15 2020-05-22 Ampel Biosolutions, Llc Machine learning disease prediction and treatment prioritization
CA3120970A1 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
JP7389980B2 (ja) 2018-12-06 2023-12-01 国立大学法人 琉球大学 ヒト膵臓組織特異的幹／前駆細胞の人工作製方法
EP3931313A2 (en) 2019-01-04 2022-01-05 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
WO2020223634A1 (en) 2019-05-01 2020-11-05 Mammoth Biosciences, Inc. Programmable nucleases and methods of use
WO2020236777A1 (en) 2019-05-20 2020-11-26 Saint Louis University Reprogramming of lipid metabolism to inhibit t cell senescence and enhance tumor immunotherapy
EP3976788A1 (en) 2019-05-30 2022-04-06 Deep Genomics Incorporated Oligonucleotide therapy for wolman disease and cholesteryl ester storage disease
BR112021025669A2 (pt) 2019-06-18 2022-02-22 Mammoth Biosciences Inc Cartucho microfluídico para detectar um ácido nucleico alvo, coletor, método para detectar um ácido nucleico alvo, e, usos de um cartucho microfluídico, de um sistema, de uma nuclease programável, de uma composição e de uma nuclease de rna programável ativada por dna
KR102726695B1 (ko) 2019-08-06 2024-11-06 현대자동차주식회사 플래그 타입 사이드 미러의 장착 구조 및 장착 방법
US11189786B2 (en) 2019-09-30 2021-11-30 International Business Machines Corporation Tapered resistive memory with interface dipoles
KR102424264B1 (ko) 2019-10-25 2022-07-25 재단법인 아산사회복지재단 피막형 여포변이 갑상선 유두암과 유두암종유사핵모양비침습소포종양 분류용 조성물 및 이를 이용한 분류 방법
AU2020388637A1 (en) 2019-11-21 2022-07-07 Remedium Bio, Inc. Growth factor restoration
EP4084796A1 (en) 2020-01-02 2022-11-09 The General Hospital Corporation Rna splicing modulation
TW202146641A (zh) 2020-03-02 2021-12-16 新加坡國立大學 用於類脂酸之生產的代謝工程技術
WO2022011037A2 (en) 2020-07-07 2022-01-13 The General Hospital Corporation Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation
US20230234928A1 (en) 2020-07-27 2023-07-27 Makscientific, Llc Novel Compounds for Treating Fibrosis and Inflammatory Conditions
US11492662B2 (en) 2020-08-06 2022-11-08 Singular Genomics Systems, Inc. Methods for in situ transcriptomics and proteomics
US11434525B2 (en) 2020-08-06 2022-09-06 Singular Genomics Systems, Inc. Spatial sequencing
WO2022061166A1 (en) 2020-09-17 2022-03-24 Mammoth Biosciences, Inc. Compositions and methods for detection of a nucleic acid
EP4213901A4 (en) 2020-09-21 2025-03-05 Massachusetts Institute of Technology COMPOUNDS, TARGETS AND PATHWAYS FOR MODULATION OF MACROPHAGES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078288A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds for use in treating cancers

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Azzarito Valeria et al.，2-O-Alkylatedpara-benzamide α-helix mimetics: the role of scaffold curvature，Organic & Biomolecular Chemistry，2012年，10(32)，pp.6469-6472
Karekar, Vaibhav V. et al.，Anexpeditious synthetic route to proteomimetic foldamers，New Journal of Chemistry，2019年，43(2)，pp.556-560
Kulikov, Oleg V. et al.，Designand Synthesis of Oligoamide-Based Double α-Helix Mimetics，European Journal of Organic Chemistry，2013年，17，pp.3433-3445
Oleg V.; Hamilton, Andrew D.，Synthesisof the novel trimeric benzamides-potential inhibitors of protein-proteininteractions，RSC Advances，2012年，2(6)，pp.2454-2461
Plante Jeffrey et al.，Synthesisof functionalised aromatic oligamide rods，Organic & Biomolecular Chemistry，2008年，6(1)，pp.138-146
REGISTRY（STN）[online]，2012.05.14[検索日 2023.11.09] CAS登録番号 1373499-79-6 他計8点
Saraogi Ishu et al.，Synthetic α-Helix Mimetics as Agonists and Antagonists of Islet Amyloid Polypeptide Aggregation，Angewandte Chemie, International Edition，2010年，49(4)，pp.736-739
Shaginian Alex et al.，Design, Synthesis and Evaluation of an α-Helix Mimetic Library Targeting Protein-Protein Interactions，Journal of the American Chemical Society，2009年，131(15)，pp.5564-5572

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024178254A (ja) * 2018-12-03 2024-12-24 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用
JP7770716B2 (ja) 2018-12-03 2025-11-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Also Published As

Publication number Publication date
EP3891123A4 (en) 2022-12-14
JP2024178254A (ja) 2024-12-24
US12275685B2 (en) 2025-04-15
EP3891123A1 (en) 2021-10-13
KR20210100115A (ko) 2021-08-13
CA3121247A1 (en) 2020-06-11
AU2019393770B2 (en) 2025-02-20
AU2019393770A2 (en) 2021-07-01
AU2019393770A1 (en) 2021-06-17
WO2020117715A1 (en) 2020-06-11
JP7770716B2 (ja) 2025-11-17
US20250304528A1 (en) 2025-10-02
US20220017454A1 (en) 2022-01-20
JP2022510374A (ja) 2022-01-26
SG11202105276TA (en) 2021-06-29

Similar Documents

Publication Publication Date Title
JP7770716B2 (ja) オリゴベンズアミド類似体およびがん処置におけるそれらの使用
CA2834778C (en) Method of treating cancer and bone cancer pain
TW299315B (https=)
EP3947351B1 (en) Small molecule parg inhibitors and methods of use thereof
US9072705B2 (en) Oligo-benzamide compounds and their use in treating cancers
CN102958364A (zh) 低聚苯甲酰胺化合物及其用途
CN109776432B (zh) 一种多靶点激酶抑制剂、药物组合物及多靶点激酶抑制剂的制备方法和应用
US12599583B2 (en) Small molecule GRB2 stabilizers for Ras map kinase inhibition
WO2011047515A1 (zh) 茚并异喹啉酮衍生物、其制备方法及其医药用途
US8835493B2 (en) Oligo-benzamide compounds for use in treating cancers
WO2018081168A2 (en) Benzothiophene-based selective mixed estrogen receptor downregulators
CN112312901B (zh) Ras癌蛋白抑制剂及其制备方法和使用方法
WO2025001997A1 (zh) 喹啉类化合物及其制备方法、药物组合物及医药用途
CN110467616A (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110407839A (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
WO2020063407A1 (zh) N-芳香酰胺类化合物及其制备方法和用途
CN111170962B (zh) 4-(苯并硒唑-2-基)芳胺类化合物治疗肠癌的用途
WO2020098516A1 (zh) 4-(苯并噻唑-2-基)芳胺类化合物治疗胃癌的用途
US20250114313A1 (en) Oligo-benzamide analogs and their use in cancer treatment
CN114456143B (zh) 一种uPA的抑制剂及其制备方法和应用
CN111689952A (zh) 含硫代四元环结构的2,3-双加氧酶抑制剂及其制备方法和用途
TW201922707A (zh) 咖啡酸衍生物及其用途
WO2022161263A1 (zh) 新型Hedgehog信号通路抑制剂
WO2025208260A1 (zh) 丙酰胺类雄激素受体拮抗剂及其制备方法和用途
CN111995629A (zh) 大根香叶衍生物及其药物组合物和其在医药中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240917

R150 Certificate of patent or registration of utility model

Ref document number: 7558167

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150